Hospira is voluntarily recalling 181,704 bags of magnesium sulfate in 5% dextrose injections because labels on the immediate container may have barcodes indicating that it is instead the blood thinner heparin.
Canadian generics maker Apotex is recalling more than 35,000 bottles of generic Zyprexa, an antipsychotic, that were manufactured at a plant in Toronto that was recently nicked by the FDA for a number of issues.
Mylan may be fending off an unsolicited $40 billion buyout offer from competitor Teva even as it is being rebuffed for making its own $31 billion bid for Perrigo, but it still has to take care of business as usual. Right now that includes having to recall 8 lots of injectable cancer drugs, most of it manufactured for Pfizer, after particulate was discovered in vials.
J&J's Janssen unit is recalling one lot of Ortho-Cept tablets because of the potential that the potency of the two active ingredients may not meet specifications, Health Canada reports.
The European Directorate for the Quality of Medicines has banned products from a Chinese maker of iodine after an inspection at its plant by French inspectors turned up contamination issues in its manufacturing processes, issues with its purified water system and a piece of testing equipment that may have been put in the facility just for show.
The McNeil Consumer Healthcare plant in Pennsylvania where a laissez-faire attitude about quality led Johnson & Johnson into a regulatory quagmire has now led the drugmaker to plead guilty to a federal misdemeanor charge and fork over $25 million.
Recalls from injectable drug specialist Hospira are a regular occurrence, but the one announced by the FDA today comes at a particularly inopportune time. The FDA posted the recall in its weekly Enforcement Report on the same day that Pfizer announced it was buying Hospira in a $17 billion deal.
A loose hair has contributed to the nationwide shortage of saline solution, as Hospira recalls another lot of the commonly used product.
Actavis has another drug recall to deal with, this one involving nearly 65,000 bottles of the generic version of the seizure drug Neurontin that it manufactures at a plant in India. The voluntary recall follows one in November of a drug that was key to its acquisition last year of Forest Pharmaceuticals.
Valeant Pharmaceuticals has started the new year with a product recall. This time the drugmaker is recalling an inhaled med that can be used to treat hospitalized infants, one which it says is suspected of having microbial contamination.